Literature DB >> 8266983

Southwestern Internal Medicine Conference: Shiga-like toxins in hemolytic-uremic syndrome and thrombotic thrombocytopenic purpura.

S L Hofmann1.   

Abstract

The majority of cases of hemolytic-uremic syndrome and a smaller proportion of cases of thrombotic thrombocytopenic purpura have recently been shown to result from a toxin produced by enteric bacteria, referred to as verotoxin, or Shiga-like toxin. The predominant toxin-producing bacterial strain in North America is E. coli O157:H7, which causes hemorrhagic colitis in humans after ingestion of contaminated meat. The toxin is believed to gain entry to the circulation from the bowel wall; it then binds to specific glycolipid receptors abundant on renal vascular endothelial cells. The toxin inactivates ribosomes inside the cells, thereby killing them and producing the clinical manifestations of hemolytic-uremic syndrome. Recognition of the etiology of hemolytic-uremic syndrome may lead to better prospects for prevention and treatment.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8266983     DOI: 10.1097/00000441-199312000-00009

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  17 in total

1.  Use of the flagellar H7 gene as a target in multiplex PCR assays and improved specificity in identification of enterohemorrhagic Escherichia coli strains.

Authors:  V P Gannon; S D'Souza; T Graham; R K King; K Rahn; S Read
Journal:  J Clin Microbiol       Date:  1997-03       Impact factor: 5.948

2.  Detection of shiga-like toxin (stx1 and stx2), intimin (eaeA), and enterohemorrhagic Escherichia coli (EHEC) hemolysin (EHEC hlyA) genes in animal feces by multiplex PCR.

Authors:  P K Fagan; M A Hornitzky; K A Bettelheim; S P Djordjevic
Journal:  Appl Environ Microbiol       Date:  1999-02       Impact factor: 4.792

3.  Murine antibody responses to the verotoxin 1 B subunit: demonstration of major histocompatibility complex dependence and an immunodominant epitope involving phenylalanine 30.

Authors:  D J Bast; J Sandhu; N Hozumi; B Barber; J Brunton
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR.

Authors:  D W Acheson; M M Levine; J B Kaper; G T Keusch
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

5.  Escherichia coli verotoxin binding to human paediatric glomerular mesangial cells.

Authors:  L A Robinson; R M Hurley; C Lingwood; D G Matsell
Journal:  Pediatr Nephrol       Date:  1995-12       Impact factor: 3.714

6.  Escherichia coli O157:H7 in microbial flora of sheep.

Authors:  I T Kudva; P G Hatfield; C J Hovde
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

7.  Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits.

Authors:  D J Bast; J L Brunton; M A Karmali; S E Richardson
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

8.  Characterization of Escherichia coli O157:H7 and other Shiga toxin-producing E. coli serotypes isolated from sheep.

Authors:  I T Kudva; P G Hatfield; C J Hovde
Journal:  J Clin Microbiol       Date:  1997-04       Impact factor: 5.948

9.  Verotoxin activates mitogen-activated protein kinase in human peripheral blood monocytes: role in apoptosis and proinflammatory cytokine release.

Authors:  Pamela Cameron; Susan J Smith; Mark A Giembycz; Dino Rotondo; Robin Plevin
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

10.  Shiga toxin 2 is specifically released from bacterial cells by two different mechanisms.

Authors:  Takeshi Shimizu; Yuko Ohta; Masatoshi Noda
Journal:  Infect Immun       Date:  2009-04-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.